Long-term Extension Study of Ligelizumab in Food Allergy

Key Inclusion Criteria: * Signed informed consent and or/assent (where applicable) obtained from participant/legal representative prior to enrolling in the rollover study and receiving study medication. If a minor participant providing assent reached the age of legal majority (as defined by local law), he/she was to be re-consented at the next study visit. * Participants had completed the treatment period in any ligelizumab's Phase III studies in food allergy. * Participants who were willing to adhere to the study visits and procedures, including receiving injections (study treatment) and participating in the OL-OFC (open label oral food challenge). * Participants who agreed to continue avoiding exposure to allergens (per core study) and any other foods they were allergic to throughout this study. * Participants who were able to safely continue into the study as judged by the investigator. Key Exclusion Criteria: * Development of a severe or life-threatening episode of an allergic reaction that required intubation and/or intensive care unit (ICU) admission during the core studies. * Development of a serious adverse event which was suspected to be related to the study treatment judged by the investigator during the core study. * Development of uncontrolled asthma during the core study that compromised the safety of the participants judged by the investigator. * Development of clinically significant cardiovascular, neurological, and or psychiatric conditions during the core …